NORD drafts comments on Senate Health, Education, Labor and Pensions committee’s discussion on FDA Safety and Landmark Advancements Act
Published: May 22, 2022
Tagged in: FDA’s Accelerated Approval Pathway, Expanded Access, Orphan Drug Act
For decades, NORD has pursued federal and state policies that will change the lives of Americans impacted by rare diseases for the better. NORD’s work can be viewed below. This page is updated daily to provide timely information. Please contact us if you have questions or need additional information.
NORD drafts comments on Senate Health, Education, Labor and Pensions committee’s discussion on FDA Safety and Landmark Advancements Act
Published: May 22, 2022
Tagged in: FDA’s Accelerated Approval Pathway, Expanded Access, Orphan Drug Act
NORD comments to HHS regarding Oregon’s proposed Medicaid 1115 waiver renewal and the importance of accelerated approval treatments
Published: Apr 13, 2022
Tagged in: FDA’s Accelerated Approval Pathway, Access to Affordable, Adequate Coverage, Medicaid Section 1115 Waivers
NORD submits a statement for the record to the Senate Committee on Health, Education, Labor and Pension regarding the FDA’s user fee agreements
Published: Apr 5, 2022
Tagged in: User Fee Act, FDA’s Accelerated Approval Pathway, Advancing Rare Disease Research and Regulatory Science